First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

BACKGROUND: The efficacy of checkpoint inhibitors for non-small cell lung cancer (NSCLC) with MET exon 14 skipping (MET

• Blasi, M.
• Kuon, J.
• Lüders, H.
• Misch, D.
• Kauffmann-Guerrero, D.
• Hilbrandt, M.
• Kazdal, D.
• Falkenstern-Ge, R. F.
• Hackanson, B.
• Dintner, S.
• Faehling, M.
• Kirchner, M.
• Volckmar, A. L.
• Kopp, H. G.
• Allgäuer, M.
• Grohé, C.
• Tufman, A.
• Reck, M.
• Frost, N.
• Stenzinger, A.
• Thomas, M.
• Christopoulos, P.